Elisabeth E. Nibbelke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elisabeth E. Nibbelke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Gerardus W. J. Frederix
Division Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Hendrik Koffijberg
University of Twente
2 shared publications - Louis J. Bont
Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Maarten O. Blanken
Division of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, P.O. Box 85090, 3508 AB, Utrecht, the Netherlands
2 shared publications - Maroeska M. Rovers
Department of Medical Imaging, Radboudumc, Nijmegen, The Netherlands
2 shared publications On Behalf Of The Dutch Rsv Neonatal Network
2 shared publications
Latest Publications
- Open Access
- 22 November 2019
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (2) , 355
Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.
- 22 November 2019
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 179 (2) , 355
Open AccessCorrection to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.
- Open Access
- 22 November 2017
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 177 (1) , 133-144
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving.Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.
- 22 November 2017
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 177 (1) , 133-144
Open AccessCost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving.Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.